Simurosertib

DB16330InvestigationalSmall molecule

Simurosertib is under investigation in clinical trial NCT03261947 (A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other...

Mechanism: Pharmacologically active on Cell division cycle 7-related protein kinase
Curator reviewed
Formula / weight: C₁₇H₁₉N₅OS · 341.43 g/mol (avg)
Code names: TAK-931

Resolves to

Compound

UNIILST350G3XUCAS1330782-76-7ChEMBLCHEMBL4297644

Structure

InChIKeyXGVXKJKTISMIOW-ZDUSSCGKSA-NSMILESCC1=NNC=C1C1=CC2=C(S1)C(=O)NC(=N2)[C@@H]1CC2CCN1CC2

Targets

O00311CDC7

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Simurosertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account